-
Je něco špatně v tomto záznamu ?
Optimizing the safety and efficacy of the awake venovenous extracorporeal membrane oxygenation in patients with COVID-19-related ARDS
P. Sklienka, F. Burša, M. Frelich, J. Máca, V. Vodička, H. Straková, M. Bílená, T. Romanová, H. Tomášková
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2018
PubMed Central
od 2016
Europe PubMed Central
od 2016
ProQuest Central
od 2007-10-01
Health & Medicine (ProQuest)
od 2007-10-01
ROAD: Directory of Open Access Scholarly Resources
od 2007
- MeSH
- antikoagulancia aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- arginin analogy a deriváty MeSH
- bdění * MeSH
- COVID-19 * komplikace terapie MeSH
- dospělí MeSH
- intervenční ultrasonografie MeSH
- kyseliny pipekolové MeSH
- lidé středního věku MeSH
- lidé MeSH
- mimotělní membránová oxygenace * škodlivé účinky metody MeSH
- retrospektivní studie MeSH
- senioři MeSH
- sulfonamidy MeSH
- syndrom dechové tísně * terapie etiologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Maintaining the patient awake and not intubated during the venovenous extracorporeal membrane oxygenation (VV ECMO) reduces the risk of ventilation-induced lung injury in patients with ARDS. Currently, there is a lack of data on outcomes and complications associated with the awake ECMO approach. OBJECTIVES: To evaluate outcomes and the occurrence of complications of awake ECMO approach guided by local safety protocol comprising ultrasound-guided cannulation, argatroban-based anticoagulation, respiratory support, and routine sedation targeted to reduce respiratory effort and keeping nurse-to-patient ratio of 1:1. DESIGN: A single-center retrospective case series analysis. METHODS: Consecutive patients with COVID-19-related acute respiratory distress syndrome (ARDS) (CARDS) treated by full awake VV ECMO approach from April 2019 to December 2023 were eligible. RESULTS: Our center treated 10 patients (mean age 54.7 ± 11.6 years) with CARDS with an awake ECMO approach. The reasons for awake ECMO included the presence of barotrauma in six patients, a team consensus to prefer awake ECMO instead of mechanical ventilation in three patients, and the patient's refusal to be intubated in one case. Before ECMO, patients were severely hypoxemic, with a mean value of Horowitz index of 48.9 ± 9.1 mmHg and a mean respiratory rate of 28.8 ± 7.3 breaths per minute on high-flow nasal cannula or noninvasive ventilation support. The mean duration of awake VV ECMO was 558.0 ± 173.6 h. Seven patients (70%) were successfully disconnected from ECMO and fully recovered. Intubation from respiratory causes was needed in three patients (30%), all of whom died eventually. In total, three episodes of delirium, two episodes of significant bleeding, one pneumothorax requiring chest tube insertion, and one oxygenator acute exchange occurred throughout the 5580 h of awake ECMO. No complications related to cannula displacement or malposition occurred. CONCLUSION: The awake ECMO strategy guided by safety protocol appears to be a safe approach in conscious, severely hypoxemic, non-intubated patients with COVID-19-related ARDS.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004193
- 003
- CZ-PrNML
- 005
- 20250527090723.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/17534666241282590 $2 doi
- 035 __
- $a (PubMed)39418135
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sklienka, Peter $u Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 17. listopadu 1790, Ostrava 70800, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 70300, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava70300, Czech Republic $1 https://orcid.org/0000000203305323 $7 xx0107715
- 245 10
- $a Optimizing the safety and efficacy of the awake venovenous extracorporeal membrane oxygenation in patients with COVID-19-related ARDS / $c P. Sklienka, F. Burša, M. Frelich, J. Máca, V. Vodička, H. Straková, M. Bílená, T. Romanová, H. Tomášková
- 520 9_
- $a BACKGROUND: Maintaining the patient awake and not intubated during the venovenous extracorporeal membrane oxygenation (VV ECMO) reduces the risk of ventilation-induced lung injury in patients with ARDS. Currently, there is a lack of data on outcomes and complications associated with the awake ECMO approach. OBJECTIVES: To evaluate outcomes and the occurrence of complications of awake ECMO approach guided by local safety protocol comprising ultrasound-guided cannulation, argatroban-based anticoagulation, respiratory support, and routine sedation targeted to reduce respiratory effort and keeping nurse-to-patient ratio of 1:1. DESIGN: A single-center retrospective case series analysis. METHODS: Consecutive patients with COVID-19-related acute respiratory distress syndrome (ARDS) (CARDS) treated by full awake VV ECMO approach from April 2019 to December 2023 were eligible. RESULTS: Our center treated 10 patients (mean age 54.7 ± 11.6 years) with CARDS with an awake ECMO approach. The reasons for awake ECMO included the presence of barotrauma in six patients, a team consensus to prefer awake ECMO instead of mechanical ventilation in three patients, and the patient's refusal to be intubated in one case. Before ECMO, patients were severely hypoxemic, with a mean value of Horowitz index of 48.9 ± 9.1 mmHg and a mean respiratory rate of 28.8 ± 7.3 breaths per minute on high-flow nasal cannula or noninvasive ventilation support. The mean duration of awake VV ECMO was 558.0 ± 173.6 h. Seven patients (70%) were successfully disconnected from ECMO and fully recovered. Intubation from respiratory causes was needed in three patients (30%), all of whom died eventually. In total, three episodes of delirium, two episodes of significant bleeding, one pneumothorax requiring chest tube insertion, and one oxygenator acute exchange occurred throughout the 5580 h of awake ECMO. No complications related to cannula displacement or malposition occurred. CONCLUSION: The awake ECMO strategy guided by safety protocol appears to be a safe approach in conscious, severely hypoxemic, non-intubated patients with COVID-19-related ARDS.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mimotělní membránová oxygenace $x škodlivé účinky $x metody $7 D015199
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a COVID-19 $x komplikace $x terapie $7 D000086382
- 650 12
- $a syndrom dechové tísně $x terapie $x etiologie $7 D012128
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a bdění $7 D014851
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000925
- 650 _2
- $a intervenční ultrasonografie $7 D018084
- 650 _2
- $a arginin $x analogy a deriváty $7 D001120
- 650 _2
- $a kyseliny pipekolové $7 D010875
- 650 _2
- $a sulfonamidy $7 D013449
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Burša, Filip $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Frelich, Michal $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Máca, Jan $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Vodička, Vojtech $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Straková, Hana $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Bílená, Markéta $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Romanová, Tereza $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 xx0332419
- 700 1_
- $a Tomášková, Hana $u Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 773 0_
- $w MED00198806 $t Therapeutic advances in respiratory disease $x 1753-4666 $g Roč. 18 (2024), s. 17534666241282590
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39418135 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250527090723 $b ABA008
- 999 __
- $a ok $b bmc $g 2263744 $s 1240200
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 18 $c - $d 17534666241282590 $e - $i 1753-4666 $m Therapeutic advances in respiratory disease $n Ther Adv Respir Dis $x MED00198806
- LZP __
- $a Pubmed-20250121